Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2018 - 2025)

Phathom Pharmaceuticals (PHAT) has 8 years of Accumulated Expenses data on file, last reported at $89.8 million in Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $89.8 million, up 68.75% year-over-year; the trailing twelve-month figure through Dec 2025 was $89.8 million (up 68.75% YoY), and the FY2025 annual result was $89.8 million, up 68.75% from the prior year.
• Accumulated Expenses climbed to $89.8 million in Q4 2025 per PHAT's latest filing, from $1.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $89.8 million in Q4 2025 and troughed at $214000.0 in Q3 2021.
• A 5-year average of $12.2 million and a median of $5.4 million in 2022 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 4545.03% in 2024 and fell as far as 88.69% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $6.3 million in 2021, then slumped by 86.54% to $854000.0 in 2022, then soared by 34.19% to $1.1 million in 2023, then soared by 4545.03% to $53.2 million in 2024, then surged by 68.75% to $89.8 million in 2025.
• Business Quant data shows PHAT's Accumulated Expenses at $89.8 million in Q4 2025, $1.4 million in Q3 2025, and $18.7 million in Q2 2025.